TScan Therapeutics adds Dr. Barbara Klencke to board and promotes three to SVP

TScan Therapeutics, Inc.

Dr. Barbara Klencke appointed to board effective April 6, 2023; granted option for 9,146 shares vesting over 36 months.
Klencke brings 20+ years oncology drug development; was CMO of Sierra Oncology (acquired by GSK in 2022).
Shrikanta Chattopadhyay promoted to SVP, Medical, Translational Medicine; 15+ years experience.
Ann Hargraves promoted to SVP, Human Resources; previously led HR at Keurig and founded Mindset Consulting.
Ray Lockard promoted to SVP, Technical Operations and Quality; over 25 years in manufacturing and supply chain.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Klencke

Director

TCRX · TScan Therapeutics, Inc.

Effective: 2023-04-06
Filed: April 10, 2023, 7:59 PM ET

On April 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Barbara Klencke, M.D., to the Board, effective April 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Barbara Klencke was appointed as Director at TScan Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Barbara Klencke, M.D., to the Board, effective April 6, 2023.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-095838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.